Background: The cure rate of standard triple therapy for Helicobacter pylori infection is unacceptably low. Susceptibility-guided therapies (SGTs) have been proposed as an alternative to standard empirical treatments. The aim of this study was to perform a systematic review and meta-analysis evaluating the efficacy of SGTs.
Introduction
Helicobacter pylori infection is one of the most frequent human infections. It is the major causative agent of chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue lymphoma (MALT) and gastric cancer. Its worldwide prevalence is nearly 50%, although there are large differences between countries. 1 Consensus conferences have recommended the combination of a proton pump inhibitor (PPI) and two antibiotics, mainly amoxicillin (1 g twice daily) and clarithromycin (500 mg twice daily) or metronidazole (500 mg twice daily) as first-line therapy for H. pylori infection. 2 -4 However, most recent data show that this combination has lost efficacy and that its cure rates are often ,70%, well below the target rate of 80% rate set during the last decade. 4 As resistance to clarithromycin is the most relevant factor predicting triple-therapy failure, 5 the increase in primary H. pylori resistance to this antibiotic has probably been the most important factor in the decrease in the efficacy of first-line triple therapy.
The overall clarithromycin resistance rate in Europe increased from 9% in 1998 to 17.6% in 2008, 4 reaching a prevalence .20% in many countries in Central, Western and Southern Europe. 6 In these regions many alternative treatments have been proposed, among them bismuth quadruple therapy, recommended as first-line therapy by the Maastricht IV/Florence consensus. 4 Other possible alternatives are non-bismuth quadruple therapies using amoxicillin, clarithromycin, metronidazole and a PPI as sequential or concomitant treatment. Finally, the Maastricht IV/Florence consensus suggests that a possible alternative may be susceptibility-guided treatment (SGT), adjusting the treatment schedule to antibiotic susceptibility in order to avoid resistance and increase cure rates. The Maastricht IV/Florence consensus recommended culture plus antibiotic susceptibility testing in order to guide third-line treatment after failure of two previous schedules. The consensus did not regard this approach as mandatory before first-and second-line treatment. By contrast, a previous meta-analysis by Wenzhen et al. 7 suggests that susceptibility-guided triple therapy is a more effective first-line treatment than standard triple therapy. However, their meta-analysis focused only on first-line treatment and found only a small number of studies. Furthermore, SGT requires endoscopy and susceptibility testing, either by culture or molecular analysis. Whether the need for invasive testing reduces the acceptability and effectiveness of SGT in clinical practice remains uncertain. Finally, the evidence regarding SGT for rescue treatment has not been systematically evaluated so far.
The aim of the present study was to perform a systematic review and meta-analysis evaluating the efficacy of SGT versus empirical therapy for both first-line and rescue H. pylori treatments.
Methods
The study was performed in accordance with the PRISMA statement. 8 The PRISMA checklist is shown in Table S1 (available as Supplementary data at JAC Online) and the PRISMA flow chart of the meta-analyses is shown in Figure 1 .
Search strategy
A systematic computerized literature search limited to full-text published articles was conducted in PubMed, Scopus, the Cochrane Library and the ISI Web of Knowledge from 1984 to March 2014 (Table S2 ). In addition, references of articles retrieved, significant reviews and the personal databases of the authors were also checked for eligible publications. Finally, all searches were repeated in February 2015 in order to include more recent articles.
Inclusion criteria
We included published full-text articles that fulfilled the following criteria: (i) they reported randomized clinical trials (RCTs) or quasi-RCTs comparing efficacy of SGT versus empirical therapy in the success of H. pylori eradication in adult patients; (ii) SGT and empirical therapy was used as first-, second-or third-line treatment; (iii) pre-treatment diagnostic tests for H. pylori detection comprised one or more of the common validated tests (urea breath test, histology, rapid urease test, stool antigen, PCR or culture); (iv) all these tests (except culture) were considered adequate as 
Risk of bias
Risk of bias was assessed independently by two reviewers (I. P. and M. B.) in accordance with the Cochrane Collaboration's current recommendations. 9 Discrepancies in interpretation were resolved with a third reviewer (X. C.). For each study, random sequence generation and allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias) and selective reporting (reporting bias) were evaluated. To assess publication bias, funnel plot asymmetry was inspected visually by examining the relationship between the treatment effects and the standard error of the estimate.
Statistical analysis
The primary endpoint for the different meta-analyses was ITT efficacy. Secondary endpoints were PP efficacy, adherence and adverse events.
For first-and second-line therapies, a meta-analysis was performed comparing eradication rates for SGT with empirical therapy in RCTs. An additional comparison was performed also including quasi-RCTs. For each comparison, eradication rates and risk ratios (RRs) were calculated with their corresponding 95% CIs and number needed to treat (NNT).
If studies differed in treatment comparisons, a random effect model was used. The I 2 statistic was used to assess the heterogeneity of the studies, following the recommendation of the Cochrane Collaboration's Handbook for Systematic Reviews of Interventions, 9 as follows: 0%-40%, not important heterogeneity; 40%-75%, moderate heterogeneity; 75% -100% considerable heterogeneity. Analyses were performed using the freeware program Review Manager (RevMan) version 5.1.
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Results
Original searches retrieved .3000 articles. Abstracts were reviewed and 37 articles were assessed for eligibility. 11 -47 After careful evaluation of the full texts, 12 were included in at least one of the meta-analyses ( Figure 1 ). Details on excluded studies are given in Table S3 .
Studies included
Twelve studies were finally included 23,29,30,33,34,36,37,40,42,44 -46 in the qualitative and quantitative analysis. A Chinese medical student helped to translate three articles, which were then included. 42, 44, 46 Seven RCTs and three quasi-RCTs were available in untreated patients, while only four RCTs were found for secondline treatment. No RCTs comparing SGT versus empirical treatment in third-line therapy were found. The characteristics of the studies are shown in Table 1 and the  treatment administered is shown in Tables 2 and 3 . The risk of bias was moderate to high in most of the studies, and is summarized in Figure 2 . As all the comparative studies but one 33 allocated the patients after endoscopy had been performed, the effectiveness and applicability of SGT in clinical practice could not be compared with non-invasive testing and empirical treatment.
First-line treatment
Six RCTs and three quasi-RCTs compared cure rates of SGT versus empirical treatment in first-line therapy 29,33,36,37,40,42,44 -46 A, amoxicillin; B, bismuth subcitrate; bid, twice a day; C, clarithromycin; E, esomeprazole; L, levofloxacin; LA, lansoprazole; M, metronidazole; O, omeprazole; qds, four times a day; NR, not reported. ( Table 1 ). The treatment administered is shown in Table 2 . Empirical treatment consisted of 7 -10 day triple therapy in all studies except one, 46 in which a bismuth-containing quadruple therapy was used. Treatment was notably more heterogeneous in the SGT arm. Most studies tested for clarithromycin resistance. Generally, patients with susceptible strains received triple therapy that included clarithromycin; those harbouring resistant strains were often treated with a combination of a PPI, amoxicillin and a nitroimidazole.
No studies reported the number of patients who did not accept endoscopy or were lost to follow-up before randomization at the time the results of culture and antibiotic susceptibility analysis were available. Only one study randomized patients before endoscopy; even in this study, patients had to accept the possibility of undergoing an endoscopy in order to be randomized. Furthermore, the study did not report how many patients refused invasive methods and had to be excluded. In consequence, there were no data on the acceptability and applicability of SGT. In summary, as no study reported the number of patients excluded for not accepting endoscopy, the effectiveness of SGT has never been evaluated either in clinical practice or in RCTs.
ITT efficacy analysis, including seven RCTs/quasi-RCTs (1958 patients), showed that SGT cure rates were superior to those of empirical treatment (RR 1.16, 95% CI 1.10 -1.23, P, 0.00001, I 2 ¼ 33%); NNT was 8 ( Figure 3) . The sub-analysis excluding quasi-RCTs (489 patients) showed similar results (RR 1.15, 95% CI 1.07 -1.24, P, 0.00001, I
2 ¼ 47%, NNT ¼ 9). PP efficacy was also significantly higher in the SGT group (RR 1.16, 95% CI 1.10-1.23, P,0.0001, I 2 ¼52%) and NNT was 8 ( Figure S1 ). PP efficacy excluding quasi-RCTs showed similar significant results (RR 1.14, 95% CI 1.06-1.22, P¼0.0006, I
2 ¼54%, NNT¼9). The sub-analysis including only studies in which triple therapy was given as empirical therapy (excluding one study 46 in which quadruple therapy containing bismuth was administered) showed similar results (ITT: RR 1.18, 95% CI 1.11 -1.26, P, 0.00001, I 2 ¼ 26%, NNT ¼ 7; PP: RR 1.18, 95% CI 1.12-1.25, P,0.00001, I
2 ¼23%, NNT¼7). The heterogeneity in all the analyses was mild to moderate (I 2 ¼ 23% -54%). The notable heterogeneity of treatments and the reduced number of studies prevented any subgroup analyses. The funnel plot showed moderate asymmetry in all the analyses, with larger studies being less favourable to SGT, thus suggesting a possible publication bias. Figure S2 shows the funnel plot for the ITT analyses of included studies.
Mild to moderate adverse events were reported in 6% -38% 29, 33, 45, 46 of patients. Two studies reported dropout rates of 1% 36 and 3% 37 due to side effects. Adverse events for the empirical treatment and SGT were rarely reported separately. In consequence, no meta-analysis could be carried out.
Second-line treatment
Four RCTs 23, 30, 33, 34 compared SGT with empirical treatment as second-line therapy. The characteristics of the studies are shown in Table 1 and the treatment administered in Table 3 . (36) Park (45) Romano (37) Wang (42) Zhou (44) Zhuo (46) Toracchio (40) Figure 3 . Forest plot of the ITT efficacy of RCTs comparing susceptibility-guided treatment with empirical treatment in first-line therapy.
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Systematic review
The meta-analysis of ITT efficacy, including 455 patients, did not show significant differences between the two therapy strategies (RR 1.11, 95% CI 0.82 -1.51, P ¼ 0.5, I
2 ¼ 87%; Figure 4 ). PP efficacy analysis, including 388 patients, showed similar results (RR 1.13, 95% CI 0.86 -1.50, P ¼ 0.38, I
2 ¼ 86%; Figure S3 ). There was considerable heterogeneity in the analyses; this fact, along with the limited number of patients, ruled out the performance of sub-analyses. Adverse events were generally mild to moderate and were reported in 65%, 30 26%, 34 and 34% of cases. 38 Only one study 34 reported severe adverse events in 4% of patients.
Discussion
The main result of the present study is that, once endoscopy and susceptibility testing are performed, SGT achieves better cure rates than 7 -10 day empirical triple therapy as first-line therapy.
The study also revealed no significant differences between SGT and empirical second-line therapy. However, few studies and high heterogeneity in rescue treatments prevent us from drawing any conclusion. Another important finding is that the evidence regarding SGT is very limited. We identified only 12 studies suitable for review-a very low figure, especially bearing in mind that a search for H. pylori treatment trials performed at the time of writing identified nearly 3000 citations. What is more, the quality of the studies was not high, and funnel plots suggest the possibility of publication bias.
An additional major limitation of the current evidence regarding SGT is that the studies evaluated SGT efficacy by randomizing patients to SGT after diagnostic endoscopy or even after successful culture. One study randomized the patients before endoscopy to empirical treatment versus SGT, but it did not report the number of patients who did not accept endoscopy and therefore were not included in the study. In clinical practice most dyspeptic patients are diagnosed with H. pylori infection in primary care by non-invasive tests and subsequently receive empirical treatment. Therefore, both burdensome additional exploration (namely endoscopy) and complex, time-consuming procedures such as culture or molecular techniques will be needed to determine antibiotic susceptibility. 2 In this setting, the need for endoscopy and the practical barriers for routine and timely H. pylori culture or genotypic evaluation of resistances may reduce the applicability of SGT. Therefore, the comparative effectiveness of SGT versus the current non-invasive diagnosis and empirical treatment policy in patients with suspected H. pylori infection has not been evaluated in RCTs and remains unclear. Further evaluation of the acceptability and applicability of SGT in clinical practice is necessary before recommending widespread SGT use.
As stated above, regarding first-line therapy, the meta-analysis of nine RCTs showed that once endoscopy and culture are performed, the efficacy of SGT is significantly higher than that of empirical 7 -0 day triple therapy, which was the standard treatment at the time that most of the studies were conducted. However, 7 or 10 day clarithromycin-containing triple therapies are currently known to achieve poor cure rates and, therefore, are suboptimal comparators. Only one study compared SGT versus bismuth-containing quadruple therapy, 46 and also showed a significantly higher efficacy in the SGT group. However, this is a further limitation of the evidence regarding SGT: there is not enough evidence comparing this approach with 14 day triple therapies or with the highly effective bismuth-and non-bismuth-containing quadruple therapies currently recommended by the Maastricht consensus. 2 The evidence supporting SGT is even more limited in rescue treatment. The meta-analysis of the four RCTs comparing SGT with empirical treatment did not find significant differences. However, these results are inconclusive, because the lack of significance may have been due to the limited power of the comparison and the reduced number of patients. Furthermore, treatment schedules in the different studies were extremely heterogeneous and the evidence regarding second-line SGT is very limited. Therefore, the conclusions of this particular meta-analysis should be interpreted with extreme care.
Regarding third-line or mixed second-and third-line treatments, no randomized controlled trials were found and most of the studies were non-comparative. In general, the cure rates with third-line therapies were not especially good with SGT and do not seem to be superior to those previously published for empirical therapies. 48 -56 A separate meta-analysis of noncomparative studies reporting cure rates of SGT in third-line treatment showed a mean cure rate of 72% (95% CI 56-87, I
2 ¼ 92%) (data not shown).
The meta-analysis highlights the need for well-designed studies evaluating the effectiveness of SGT either as a first-line therapy or as a rescue therapy. A study evaluating SGT effectiveness as a first-line treatment should randomize patients with uninvestigated dyspepsia to non-invasive testing or endoscopy plus culture. For second-or third-line treatment, the study should randomize patients with a positive control test to endoscopy and culture versus empirical treatment.
In conclusion, the currently available evidence suggests that SGT is superior to 7 -10 day triple therapies as first-line treatment in patients who have already undergone endoscopy and culture. There is lack of strong evidence to support SGT in rescue treatment. There is an urgent need for data regarding the effectiveness and acceptability of SGT in clinical practice. Data are also needed on its efficacy in comparison with the highly effective quadruple therapies, which are currently recommended. Overall, the evidence is too limited to support the generalized use of SGT for H. pylori treatment, either as first-line or as rescue treatment; more studies will be needed to reach an evidencebased conclusion. However, once endoscopy and culture are performed, the use of SGT seems to increase cure rates and may therefore be effective in specific situations. As for rescue treatments, the efficacy of more intensive schedules, such as long quadruple therapies, either associated with SGT or not, deserves further study.
